Eurobio Scientific's Growth Story Faces a €48 Million Cliffhanger

PARIS, FRANCE – April 10, 2026 – Eurobio Scientific has unveiled a robust set of 2025 annual results, painting a picture of a company successfully executing a high-stakes strategic pivot. The in vitro diagnostics specialist reported a 9% rise in annual revenue to €168.3 million and an impressive 22% jump in net income to €4.9 million. These figures, however, are overshadowed by a formidable challenge looming on the horizon: the confirmed termination of its long-standing distribution agreement with South Korean partner Seegene, a deal that accounted for nearly 30% of its revenue in the past year.

The results highlight a critical duality in the company's narrative. On one hand, its strategic shift toward higher-margin proprietary products and aggressive international expansion is clearly paying dividends. On the other, it now faces a race against time to fill a projected €48 million revenue gap before the Seegene contract fully unwinds, a test that will define its future trajectory.

A Strategic Pivot Bears Fruit

The core of Eurobio Scientific's success in 2025 lies in the accelerated growth of its own products. Sales of these proprietary diagnostics and reagents surged by 20%, a rate more than double the company's overall growth. This has pushed the contribution from proprietary products to nearly 35% of total revenue, up from 32% in 2024, bringing the company closer to its medium-term goal of 50%.

This shift is not just about revenue volume; it's a fundamental move toward greater profitability and self-reliance. The strategy's effectiveness is evident in key growth areas. The GenDx subsidiary, a specialist in HLA typing for transplant diagnostics acquired in late 2022, continued its strong performance with a 9% revenue increase to €33.5 million. This unit has become a cornerstone of the company's international presence, particularly in the high-value U.S. market.

Further bolstering the proprietary portfolio are the EndoPredict® and Prolaris® genomic tests for breast and prostate cancer, acquired from Myriad Genetics in mid-2024. These products contributed €4.9 million in revenue in 2025 and represent a significant push into the lucrative oncology diagnostics space. The company has since consolidated their production, moving operations from Germany to France to streamline costs and operations, a move that incurred some non-recurring costs but is central to its integration strategy.

International expansion has been the other powerful engine of growth. Sales outside of France now account for 42% of total revenue. This was fueled by a string of strategic acquisitions designed to build a direct presence in key European markets. The takeovers of Quimark and the Life Sciences unit of Voden Medical Instruments in Italy during 2025 added a combined €5 million to the top line, providing immediate market access and new cross-selling opportunities for the group's expanding portfolio.

The Seegene Elephant in the Room

Despite the clear momentum from its strategic initiatives, the central topic of concern for investors is the impending loss of the Seegene distribution agreement. The partnership, a fixture since 2011, generated approximately €48 million in 2025. Seegene has formally signaled its intent to establish a direct presence in the French market beginning January 1, 2027, effectively ending its reliance on Eurobio Scientific as its distributor.

The sheer scale of this revenue stream—representing nearly 30% of the company's business—makes its loss a significant operational and financial challenge. In its announcement, Eurobio Scientific noted that contractual provisions allow it to continue fulfilling certain public and private contracts for up to three years beyond the termination date. This provides a crucial, albeit temporary, cushion that will phase out the revenue loss rather than create an immediate cliff-edge drop.

Nonetheless, this buffer does not solve the underlying problem. The company's leadership is now under immense pressure to demonstrate that its proprietary product pipeline and international expansion can accelerate fast enough not only to continue overall growth but also to backfill this massive, looming hole in its revenue base. The success or failure of this effort will be the primary determinant of the company's valuation and market standing over the next two to three years.

Pressure Beneath the Surface

A deeper dive into the financial statements reveals the pressures inherent in the company's transformation. While headline revenue and net income were strong, EBITDA remained flat at €27.4 million, identical to 2024. More telling, operating income (excluding certain amortization charges) fell 11% to €19.7 million.

This squeeze on profitability is driven by two main factors. First, the gross margin dipped slightly by 0.8 percentage points to 45.5%, a decline the company attributes to structural price erosion and reimbursement pressures, particularly within its legacy distribution business in France. This highlights precisely why the pivot to higher-margin proprietary products is so critical.

Second, operating expenses rose significantly as a direct result of the growth strategy. Marketing and sales expenses climbed 17% to €34.3 million, a necessary investment to support recent acquisitions and strengthen the commercial teams tasked with promoting proprietary products. General and administrative expenses also increased by 16% to €18.7 million, inflated by acquisition-related scope changes and non-recurring costs tied to the reorganization of its German operations.

These figures illustrate the financial trade-off at the heart of Eurobio Scientific's strategy: it must spend money to grow its more profitable segments, even as its legacy business faces margin compression. Maintaining this investment while preparing for the Seegene revenue loss will require disciplined cost management and a sharp focus on execution.

Fortifying the Foundation for the Fight Ahead

To finance this transition, Eurobio Scientific is leveraging a restructured balance sheet under its majority owner, EB Development, a holding company backed by IK Partners and NextStage AM. The company ended 2025 with a net cash position of -€1.9 million, a figure that includes €20.6 million in cash but also reflects financial debt and a €12.4 million current account owed to EB Development. Despite this, the company generated a stable free cash flow of €6 million in 2025, demonstrating its ability to fund its operations and investments.

A significant portion of its capital continues to be deployed for non-organic growth, with a net outflow of €12.9 million for investing activities in 2025, primarily for acquisitions. This M&A-driven strategy remains a key tool for accelerating its entry into new markets and acquiring new technologies.

As Eurobio Scientific prepares for its annual general meeting in June, its path is clearly defined. The company has successfully ignited its proprietary growth engine, a vital step in securing its long-term health and profitability. Yet, with the clock ticking on its most significant distribution contract, the race is now on to see if that new engine can generate enough power to overcome the massive revenue chasm that lies just ahead.